Department of Psychiatry, Obstetrics and Gynecology, University of Colorado Denver, Aurora, USA.
Am J Psychiatry. 2013 Mar;170(3):290-8. doi: 10.1176/appi.ajp.2012.12070940.
Deficient cerebral inhibition is a pathophysiological brain deficit related to poor sensory gating and attention in schizophrenia and other disorders. Cerebral inhibition develops perinatally, influenced by genetic and in utero factors. Amniotic choline activates fetal α7-nicotinic acetylcholine receptors and facilitates development of cerebral inhibition. Increasing this activation may protect infants from future illness by promoting normal brain development. The authors investigated the effects of perinatal choline supplementation on the development of cerebral inhibition in human infants.
A randomized placebo-controlled clinical trial of dietary phosphatidylcholine supplementation was conducted with 100 healthy pregnant women, starting in the second trimester. Supplementation to twice normal dietary levels for mother or newborn continued through the third postnatal month. All women received dietary advice regardless of treatment. Infants' electrophysiological recordings of inhibition of the P50 component of the cerebral evoked response to paired sounds were analyzed. The criterion for inhibition was suppression of the amplitude of the second P50 response by at least half, compared with the first response.
No adverse effects of choline were observed in maternal health and delivery, birth, or infant development. At the fifth postnatal week, the P50 response was suppressed in more choline-treated infants (76%) compared with placebo-treated infants (43%) (effect size=0.7). There was no difference at the 13th week. A CHRNA7 genotype associated with schizophrenia was correlated with diminished P50 inhibition in the placebo-treated infants, but not in the choline-treated infants.
Neonatal developmental delay in inhibition is associated with attentional problems as the child matures. Perinatal choline activates timely development of cerebral inhibition, even in the presence of gene mutations that otherwise delay it.
大脑抑制不足是一种与精神分裂症和其他疾病的感觉门控和注意力差有关的病理脑缺陷。大脑抑制是在围产期发展的,受遗传和宫内因素的影响。羊水中的胆碱能激活胎儿的α7-烟碱型乙酰胆碱受体,并促进大脑抑制的发展。增加这种激活可能通过促进正常的大脑发育来保护婴儿免受未来疾病的影响。作者研究了围产期胆碱补充对人类婴儿大脑抑制发展的影响。
对 100 名健康孕妇进行了随机安慰剂对照的饮食磷脂酰胆碱补充临床试验,从妊娠中期开始。母亲或新生儿的补充量增加到正常饮食水平的两倍,持续到第三个产后月。所有妇女无论接受何种治疗都接受饮食建议。对婴儿的脑诱发电位对成对声音的 P50 成分的抑制进行电生理记录分析。抑制的标准是与第一个反应相比,第二个 P50 反应的振幅至少被抑制一半。
在母亲的健康和分娩、出生或婴儿发育方面,没有观察到胆碱的不良影响。在第五个产后周,与安慰剂组相比,胆碱治疗组的婴儿(76%)的 P50 反应抑制更为明显(效应量=0.7)。在第 13 周时没有差异。与精神分裂症相关的 CHRNA7 基因型与安慰剂治疗组婴儿的 P50 抑制减少相关,但与胆碱治疗组婴儿无关。
抑制的新生儿发育延迟与儿童成熟时的注意力问题有关。围产期胆碱能激活大脑抑制的及时发展,即使存在其他会延迟其发展的基因突变也是如此。